01.12.2010
VentiRx Pharmaceuticals Raises $25 Million in Series A Extension Financing - Funds used for clinical development of the first selective TLR8 agonists

04.16.2009
VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis - First Selective TLR8 Agonist to Advance for Treatment of Allergy

12.04.2008
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology - First Selective TLR8 Agonist to Advance to Clinical Trials

05.23.2008
VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors

04.16.2007
VentiRx Pharmaceuticals Appoints Kent Snyder to Board of Directors

03.13.2007
Array BioPharma and VentiRx Pharmaceuticals Announce License Agreement

03.06.2007
VentiRx Pharmaceuticals Announces $28.9 Million Financing